Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
SARS-CoV-2 will probably continue to circulate indefinitely, and animal coronaviruses may emerge at any time.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.
Some think the U.S. should have had an equivalent of Operation Warp Speed for COVID-19 testing.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
COVID-19 vaccines are highly effective, but people with a low CD4 count or detectable viral load are at risk for poor response.
Boosters further reduce the risk of severe illness and can help curb coronavirus transmission.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
CDC study shows vaccine-induced immunity is stronger, but others found post-infection immunity more protective.
Many people who received any of the authorized COVID-19 vaccines are now eligible for an additional dose of their choice.
Co-occurring health disorders appear to contribute to increased risk, NIH study suggests.
A growing number of transplant programs are barring patients who refuse COVID vaccines or giving them lower priority on waiting lists.
People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.
Excess deaths by population were three to four times higher among Black and American Indian men and women.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.